Thyroid-related eye disease
Conditions
Interventions
Experimental Group:teprotumumab treatment
Sponsors
Shanghai Tenth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Meet the TED diagnostic criteria; 2.EUGOGO classification: Moderate to severe; 3. Age: 18-80 years old 4. The subjects are willing and able to abide by the prescribed treatment plan and assessment time.
Exclusion criteria
Exclusion criteria: 1. Known to be allergic to any component of testuzumab or have had a previous allergic reaction to monoclonal antibody drugs; 2. Pregnant women, those with prohibited implants in their bodies, or those with claustrophobia who are not suitable for PET/MRI; 3. There are any other pre-existing diseases, metabolic disorders, abnormal physical examination or clinical laboratory test results, and there is reason to suspect that there may be diseases or conditions that lead to contraindications for the use of the investigational drug, or affect the interpretation of the research results, or put the subjects at high risk of treatment complications; 4. During the study period, other treatments for TED were received, including drug therapy (local or systemic glucocorticoids, traditional immunosuppressants and other biological agents), orbital radiotherapy, or surgical treatment, etc. 5. Those who the researchers believe are not suitable to participate in this clinical trial for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Molecular imaging parameters of 18F-FAPI & FDG PET/MRI; | — |
Countries
China
Contacts
Public ContactChunjun Sheng, Chao Ma
Shanghai Tenth People's Hospital
Outcome results
None listed